文献速递新发突发、热带与寄生虫病

每周双氢青蒿素-哌喹与每月磺胺多辛-乙胺嘧啶在乌干达和马拉维镰状细胞贫血儿童疟疾化学预防中的比较(CHEMCHA):一项随机、双盲、安慰剂对照试验

Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Infect Dis · 2024-12-20

在乌干达和马拉维的4家医院开展随机双盲安慰剂对照试验,725名6月龄至15岁镰状细胞贫血儿童随机接受每周双氢青蒿素-哌喹或每月磺胺多辛-乙胺嘧啶。双氢青蒿素-哌喹组临床疟疾发生率8.8例/100人年,磺胺多辛-乙胺嘧啶组43.7例/100人年(IRR 0.20,95%CI 0.14-0.30,p<0.0001)。

要点

  • 每周双氢青蒿素-哌喹较每月磺胺多辛-乙胺嘧啶显著降低临床疟疾发生率(IRR 0.20)。
  • 双氢青蒿素-哌喹组疟疾住院和输血次数更少,但下呼吸道事件住院更多。
  • 在磺胺多辛-乙胺嘧啶耐药地区,5岁以下接受青霉素预防的患儿可考虑双氢青蒿素-哌喹。

核心结论

  • 在镰状细胞贫血儿童中,每周双氢青蒿素-哌喹预防疟疾安全且效果显著优于每月磺胺多辛-乙胺嘧啶。
  • 在高度磺胺多辛-乙胺嘧啶耐药的地区,5岁以下接受青霉素V预防的镰状细胞贫血患儿可考虑双氢青蒿素-哌喹作为磺胺多辛-乙胺嘧啶的替代方案。
  • 5岁以上儿童仍需进一步研究。

研究设计与样本

  • 在乌干达2家和马拉维2家医院开展的个体随机、平行组、双盲、安慰剂对照试验。
  • 纳入6月龄至15岁、体重至少5kg的镰状细胞贫血儿童,按1:1计算机生成区组随机分组,按中心和体重类别分层。
  • 干预为每周双氢青蒿素-哌喹(约2.5 mg/kg双氢青蒿素和20 mg/kg/天哌喹)或每月磺胺多辛-乙胺嘧啶(约25 mg/kg磺胺多辛和1.25 mg/kg乙胺嘧啶)。
  • 所有5岁以下儿童接受每日两次青霉素作为标准治疗。
  • 2021年4月17日至2022年5月30日随机分配725名参与者,724名纳入主要分析(双氢青蒿素-哌喹组367名,磺胺多辛-乙胺嘧啶组357名)。

主要发现

  • 临床疟疾发生率:双氢青蒿素-哌喹组8.8例/100人年 vs 磺胺多辛-乙胺嘧啶组43.7例/100人年(IRR 0.20,95%CI 0.14-0.30,p<0.0001)。
  • 疟疾住院发生率:双氢青蒿素-哌喹组10.4例/100人年 vs 磺胺多辛-乙胺嘧啶组37.0例/100人年(IRR 0.29,95%CI 0.20-0.42,p<0.0001)。
  • 输血次数:双氢青蒿素-哌喹组52.1例/100人年 vs 磺胺多辛-乙胺嘧啶组72.5例/100人年(IRR 0.70,95%CI 0.54-0.90,p=0.006)。
  • 非疟疾相关门诊就诊:双氢青蒿素-哌喹组更多(IRR 1.12,95%CI 1.00-1.24,p=0.042)。
  • 下呼吸道事件住院:双氢青蒿素-哌喹组16.5例/100人年 vs 磺胺多辛-乙胺嘧啶组8.5例/100人年(IRR 1.99,95%CI 1.25-3.16,p=0.0036)。

临床怎么用

  • 在高度恶性疟原虫抗叶酸耐药的地区,5岁以下接受青霉素V预防的镰状细胞贫血患儿可考虑每周双氢青蒿素-哌喹作为疟疾化学预防的替代方案。
  • 5岁以上儿童使用双氢青蒿素-哌喹仍需进一步研究。

局限性

  • 5岁以上儿童需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In many sub-Saharan African countries, it is recommended that children with sickle cell anaemia receive malaria chemoprevention with monthly sulfadoxine-pyrimethamine or daily proguanil as the standard of care. However, the efficacy of these interventions is compromised by high-grade antifolate resistance of Plasmodium falciparum and poor adherence. We aimed to compare the efficacy of weekly dihydroartemisinin-piperaquine and monthly sulfadoxine-pyrimethamine for the prevention of clinical malaria in children with sickle cell anaemia in areas with high-grade sulfadoxine-pyrimethamine resistance of P falciparum in Uganda and Malawi. METHODS: We did an individually randomised, parallel group, double-blind, placebo-controlled trial at two hospitals in Uganda and two hospitals in Malawi. Children (aged 6 months to 15 years) with sickle cell anaemia with a bodyweight of at least 5kg were randomly assigned (1:1) by computer-generated block randomisation, stratified by site and weight category, to receive either weekly dihydroartemisinin-piperaquine (approximately 2·5 mg per kg bodyweight dihydroartemisinin and 20 mg per kg bodyweight per day piperaquine) or monthly sulfadoxine-pyrimethamine (approximately 25 mg per kg bodyweight sulfadoxine and 1·25 mg per kg bodyweight). Placebos matching the alternative treatment were used in each treatment group to maintain masking of the different dosing schedules from the participants and caregivers, study staff, investigators, and data analysts. All children younger than 5 years received penicillin twice daily as standard of care. The primary endpoint was the incidence of clinical malaria, defined as a history of fever in the preceding 48 h or documented axillary temperature of 37·5°C or higher plus the detection of P falciparum parasites on microscopy (any parasite density). Secondary efficacy outcomes were any malaria parasitaemia (on either microscopy or malaria rapid diagnostic test), all-cause unscheduled clinic visits, all-cause and malaria-specific hospitalisation, sickle cell anaemia-related events (including vaso-occlusive crises, acute chest syndrome, stroke), need for blood transfusion, and death. All primary and secondary outcomes were assessed in the modified intention-to-treat population, which included all participants who were randomly assigned for whom endpoint data were available. Safety was assessed in in all children who received at least one dose of the study drug. Complete case analysis was conducted using negative-binomial regression. This study was registered with Clinicaltrials.gov, NCT04844099. FINDINGS: Between April 17, 2021, and May 30, 2022, 725 participants were randomly assigned; of whom 724 were included in the primary analysis (367 participants in the dihydroartemisinin-piperaquine group and 357 participants in the sulfadoxine-pyrimethamine group). The median follow-up time was 14·7 months (IQR 11·2-18·2). The incidence of clinical malaria was 8·8 cases per 100 person-years in the dihydroartemisinin-piperaquine group and 43.7 events per 100 person-years in the sulfadoxine-pyrimethamine group (incidence rate ratio [IRR] 0·20 [95% CI 0·14-0·30], p<0·0001). The incidence of hospitalisation with any malaria was lower in the dihydroartemisinin-piperaquine group than the sulfadoxine-pyrimethamine group (10·4 vs 37·0 events per 100 person-years; IRR 0·29 [0·20-0·42], p<0·0001) and the number of blood transfusions was also lower in the dihydroartemisinin-piperaquine group than the sulfadoxine-pyrimethamine group (52·1 vs 72·5 events per 100 person-years; IRR 0·70 [0·54-0·90], p=0·006). The incidence of all-cause unscheduled clinic visits and all-cause hospitalisations were similar between the two groups, however, participants in the dihydroartemisinin-piperaquine group had more clinic visits unrelated to malaria (IRR 1·12 [1·00-1·24], p=0·042) and more hospitalisations with lower respiratory tract events (16·5 vs 8·5 events per 100 person-years; IRR 1·99 [1·25-3·16], p=0·0036) than participants in the sulfadoxine-pyrimethamine group. The number of serious adverse events in the dihydroartemisinin-piperaquine group was similar to that in the sulfadoxine-pyrimethamine group (vaso-occlusive crisis [154 of 367 participants dihydroartemisinin-piperaquine group vs 132 of 357 participants in the sulfadoxine-pyrimethamine group] and suspected sepsis [115 participants vs 92 participants]), with the exception of acute chest syndrome or pneumonia (51 participants vs 32 participants). The number of deaths were similar between groups (six [2%] of 367 participants in the dihydroartemisinin-piperaquine group and eight (2%) of 357 participants in the sulfadoxine-pyrimethamine group). INTERPRETATION: Malaria chemoprophylaxis with weekly dihydroartemisinin-piperaquine in children with sickle cell anaemia is safe and considerably more efficacious than monthly sulfadoxine-pyrimethamine. However, monthly sulfadoxine-pyrimethamine was associated with fewer episodes of non-malaria-related illnesses, especially in children 5 years or older not receiving penicillin prophylaxis, which might reflect its antimicrobial effects. In areas with high P falciparum antifolate resistance, dihydroartemisinin-piperaquine should be considered as an alternative to sulfadoxine-pyrimethamine for malaria chemoprevention in children younger than 5 years with sickle cell anaemia receiving penicillin-V prophylaxis. However, there is need for further studies in children older than 5 years. FUNDING: Research Council of Norway and UK Medical Research Council. TRANSLATIONS: For the Chichewa, Acholi, Lusoga and Luganda translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Idro R, Nkosi-Gondwe T, Opoka R, et al. Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2024. PMID: 39718172. doi:10.1016/S1473-3099(24)00737-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。